H.B. Fuller Company research snapshot
FUL AI stock analysis as of the August 4, 2026 data cutoff reads H.B. Fuller as a 139-year-old pure-play industrial adhesives company that is executing well but carries elevated leverage and a pending medical acquisition overhang. The stock closed at $57.01 on August 3, 2026, up 1.71 or 3.09% from the $55.30 close on July 31, after opening at $56.14 and trading in a session range of $56.08 to $57.31, carrying a market capitalization near $3.07 billion. Fiscal Q2 2026, reported June 25, 2026, delivered net revenue of $950.27 million, up 5.8% year over year, with adjusted EBITDA of $181 million, up 9%, an EBITDA margin of 19.1% up 70 basis points, adjusted EPS of $1.41, up 19%, and record second-quarter operating cash flow of $121 million, with the company repurchasing about 750,000 shares. Management raised fiscal 2026 adjusted EBITDA guidance to $650 million to $675 million and adjusted EPS to $4.60 to $4.90. The all-cash offer to acquire Advanced Medical Solutions, announced June 24, 2026, at GBP 2.85 per share for an enterprise value of about GBP 715 million, roughly $942 million including debt, is expected to close by the end of calendar 2026 and would lift net leverage to about 4x before synergies, with a planned return to the 2.5x to 3x target range within two years of closing. The stock trades at about 16.9x trailing earnings and 11.1x forward earnings, with the Street at a Strong Buy consensus and an average target of $73.29, about 28.6% above the price.
Current price
$57.01 at the August 3, 2026, 4:00 PM EDT market close, up 1.71 or 3.09% from the $55.30 July 31 close, after opening at $56.14 and trading in a session range of $56.08 to $57.31, with an after-hours quote of $55.91, down 1.10 or 1.93%
Market cap
$3.07 billion reported by StockAnalysis.com at the August 3, 2026 market close, matching the $57.01 price times 53.79 million shares outstanding
AI score
60 / 100
Rating
Improving adhesives operator with elevated leverage and AMS deal overhang
Trend status
Recovering sideways trend above the 5-day and 20-day moving averages near $56 but below the 50-day near $59.42 and the 200-day near $60.10, after a June drop on the AMS acquisition news
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | H.B. Fuller is a 139-year-old formulator and manufacturer of industrial adhesives, sealants, coatings, and specialty polymers. Three segments: Hygiene, Health and Consumable Adhesives, about 44% of TTM revenue, Engineering Adhesives, about 31%, and Building Adhesive Solutions, about 25%. Revenue is recurring from large packaging, hygiene, construction, automotive, and electronics customers, and the second quarter showed improving pricing execution. | High |
| Moat | The moat is moderate. Long-standing customer relationships, formulation expertise, regulatory certifications, and a global manufacturing footprint create real switching costs once an adhesive is qualified on a production line. No network effects or patent wall. Competitors include Henkel, Sika, RPM International, and 3M. The AMS deal would deepen regulatory and medical qualification barriers. | Medium |
| Management | CEO Celeste Beeks Mastin, in place since 2023, is executing a pricing, sourcing, and restructuring agenda. Q2 2026 delivered revenue up 5.8%, adjusted EBITDA up 9%, adjusted EPS up 19%, record second-quarter cash flow, and a full-year guidance raise, while about 750,000 shares were repurchased. The AMS acquisition is the defining strategic move and has drawn public opposition from Ancora Holdings, creating governance uncertainty. | Medium |
| Financial trend | Fiscal Q2 2026 net revenue was $950.27 million, up 5.8% year over year, adjusted EBITDA was $181 million, up 9%, with the margin at 19.1% up 70 basis points, adjusted EPS was $1.41, up 19%, and operating cash flow of $121 million was a record for a second quarter. Fiscal 2026 guidance was raised to adjusted EBITDA of $650 million to $675 million and adjusted EPS of $4.60 to $4.90. TTM revenue is about $3.51 billion and TTM net income about $185.7 million. | High |
| Valuation | At about 16.9x trailing earnings, 11.1x forward earnings, 0.87x sales, 1.47x book value, and 9.2x EV/EBITDA, FUL is reasonably valued for an improving mid-cap chemical company, with the forward multiple reflecting the leverage and acquisition overhang. Before the June 24 AMS announcement the stock traded near $64.60; the current $57.01 price implies the market is still discounting deal and integration risk. | Medium |
| Technical trend | FUL closed at $57.01 on August 3, 2026, up 3.09%, above its computed 5-day moving average near $56.11 and 20-day moving average near $56.19, but below the 50-day moving average near $59.42 and the 200-day near $60.10 reported by StockAnalysis.com. The stock ranged between roughly $53.90 and $58.40 through late July after the mid-$64 level on June 24, with 14-day RSI near 48.87, a neutral reading. | Medium |
| Risk level | Elevated. Total debt is about $2.07 billion against cash near $114 million, net leverage is about 3.1x and would rise to roughly 4x pro forma on the AMS deal, the TTM net margin is thin at about 5.3%, the second-half outlook assumes volumes down mid-single digits, raw material costs remain elevated with about 52 force majeures still in place, and Ancora Holdings publicly opposes the acquisition. | Medium |
| AI confidence | High for descriptive analysis of historical financials and market data that cross-validated across StockAnalysis.com, SEC EDGAR XBRL, and the Q2 2026 earnings call. Lower for forward returns because the AMS acquisition will reshape the business profile, balance sheet, and earnings trajectory in ways not fully specified until close. | High data confidence |
| Investment certainty | Medium-low. The adhesives business is durable with real switching costs and a credible 2026 guidance path, but the leverage profile and the pending AMS transaction create a risk/reward setup where the downside scenarios are more probable until the deal closes, integrates, and deleverages as planned. | Medium-low |
FUL AI stock forecast
The FUL AI stock forecast should be read as scenario math, not a price promise. Using the $57.01 August 3, 2026 close, fiscal 2026 consensus adjusted EPS of about $4.87, and a three-year framework, the tested range spans a bearish area near $51, a base area near $74, and a bullish area near $100. These outputs depend on adjusted EPS growth, AMS deal close and integration, debt reduction progress, raw material costs, end-market volume, and the terminal earnings multiple.
$94 to $108
More likely if the AMS deal closes by the end of 2026, the about $55 million of identified run-rate synergies are captured on schedule, medical becomes a high-single-digit-growth fourth segment, net leverage returns to the 2.5x to 3x target within two years, and the market re-rates adjusted EPS toward a 14x to 15x multiple as margins approach the 20% EBITDA target.
$68 to $80
More likely if FUL compounds adjusted EPS near the 8% to 9% consensus path from $4.87 toward about $6.20 over three years, the AMS deal closes with some integration friction and temporarily elevated leverage, the 2026 guidance path of adjusted EBITDA of $650 million to $675 million and adjusted EPS of $4.60 to $4.90 is met, and the market holds the multiple near 12x to 12.5x forward earnings.
$46 to $56
More likely if the AMS deal is delayed, renegotiated, or blocked, integration costs erode margins, a recession or soft consumer demand pushes volumes down more than the guided mid-single-digit decline, raw material costs stay elevated, or the multiple contracts toward 9x to 10x forward earnings on leverage and cyclical concerns.
FUL AI technical analysis
FUL technical analysis as of the August 4, 2026 data cutoff shows a recovering sideways range. The stock closed at $57.01 on August 3, 2026, up 1.71 or 3.09%, after opening at $56.14 and trading in a session range of $56.08 to $57.31. It sits above the 5-day moving average near $56.11 and the 20-day moving average near $56.19 computed from the StockAnalysis.com daily price history, but below the 50-day moving average near $59.42 and the 200-day moving average near $60.10 reported by StockAnalysis.com statistics. The 14-day RSI is near 48.87, neutral. Beta is about 0.97, near market-level volatility. Data cutoff: August 3, 2026 close.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $57.01 | StockAnalysis.com real-time quote at the August 3, 2026, 4:00 PM EDT market close, up 1.71 or 3.09% from the $55.30 July 31 close, after opening at $56.14 and trading in a session range of $56.08 to $57.31; the after-hours quote was $55.91, down 1.10 or 1.93%. |
| 5-day moving average | $56.11 | Computed as the simple average of the five closing prices through August 3, 2026 in the StockAnalysis.com daily price history, just below the current price, which signals short-term momentum is turning positive. |
| 20-day moving average | $56.19 | Computed as the simple average of the twenty closing prices through August 3, 2026 in the StockAnalysis.com daily price history, just below the current price and acting as near-term support. |
| Near support | $53.90 to $55.30 | The July 31 intraday low was $53.86 and the July 31 close was $55.30. A hold of this zone keeps the recent sideways range intact. |
| Major support (52-week low) | $48.71 | The 52-week low from the StockAnalysis.com quote. A decisive break below with volume would indicate the market is pricing in a materially worse AMS deal outcome. |
| Near resistance | $59.42 | The 50-day moving average reported by StockAnalysis.com statistics on August 3, 2026, is the first meaningful overhead level above the range. |
| Next resistance | $60.10 | The 200-day moving average reported by StockAnalysis.com statistics on August 3, 2026. A reclaim of both the 50-day and 200-day would shift the technical posture bullish. |
| Pre-announcement level | $64.60 | The June 24, 2026 close just before the Advanced Medical Solutions acquisition announcement. Recovery to this area would signal the market has accepted the deal terms. |
| Momentum | RSI near 48.87 | The 14-day RSI on StockAnalysis.com statistics on August 3, 2026 was neutral, consistent with a sideways range rather than an overbought or oversold condition. |
| Volume | About 718,000 average shares | StockAnalysis.com statistics listed 20-day average volume near 718,408 shares on August 3, 2026, with the August 3 session showing about 566,000 shares traded, below average. |
| Volatility | Near-market | Beta is about 0.97 on StockAnalysis.com statistics, so FUL tends to move roughly in line with the market, but the AMS deal creates event-driven gaps around approval and close news. |
| Invalidation | Close below $53.86 | A decisive daily close below the July 31 intraday low of $53.86 would weaken the range and open the path toward the $48.71 52-week low; a close above $60.10 would turn the medium-term trend bullish. |
FUL AI trading strategy
The FUL AI trading strategy framework below is provided for informational reference, not personalized advice. H.B. Fullers leverage profile, the pending AMS acquisition, and cyclical end-market exposure create distinct patterns that traders may incorporate into systematic approaches. Use Pineify stock screener and Pine Script builder to design and backtest your own strategy conditions.
FUL has been trading in a roughly $53.90 to $58.40 range since early July. A mean-reversion trader can look for entries near the $53.90 to $55.30 support zone with exits near the $58.40 to $59.42 resistance band, treating the 50-day moving average near $59.42 as the primary profit-taking area.
Risk per trade 1% to 2% of capital. Stop below $53.50, with invalidation on a daily close under $53.86 that opens the path to $48.71. Position size should reflect that the AMS approval timeline can cause gaps through stops.
The Advanced Medical Solutions deal creates a binary catalyst. Monitor for regulatory clearance, the AMS shareholder meeting, the expected close by the end of calendar 2026, and any updated synergy or financing disclosures. A long entry on confirmed deal progress near current levels with a stop under the 52-week low could capture the re-rating if leverage concerns fade.
Risk per trade 1% to 2% given the binary event. Stop at or below $48.71. Invalidation: deal collapse, renegotiation at worse terms, or financing stress. Consider reducing size given the uncertainty around timing.
If FUL reclaims and holds the 50-day moving average near $59.42 and then the 200-day near $60.10, the medium-term trend turns bullish. Entries on a confirmed close above $60.10 with expanding volume target the pre-announcement area near $64.60 and beyond.
Risk per trade 2% to 3% after confirmation. Initial stop below $57.00 or the 20-day moving average near $56.19, trailing higher as price extends. Abort the setup if volume does not confirm the breakout.
Investment research summary
H.B. Fuller sells adhesives that hold together packaging, diapers, electronics, cars, buildings, and aircraft. Customers pay for formula reliability, production-line compatibility, and global supply assurance, especially valuable during the current petrochemical supply dislocation, and the second quarter showed pricing power of about 3% with 2.6% organic growth.
Moderate moat from customer relationships and qualification cycles, formulation expertise, regulatory certifications in food, hygiene, and medical applications, and a global manufacturing footprint. Competitors include Henkel, Sika, RPM International, and 3M. No network effects or strong patent wall, but the AMS acquisition would add medical-device regulatory barriers and a deeper qualification moat.
Worst case: the AMS acquisition burdens the balance sheet with roughly $1 billion of incremental committed financing at about 12.9x pre-synergy EBITDA, integration fails to deliver the about $55 million of run-rate synergies, a recession pushes volumes down more than the guided mid-single-digit decline, raw material costs stay elevated, and net margins near 5% compress to breakeven, forcing covenant pressure or a distressed equity raise.
CEO Celeste Beeks Mastin, in place since 2023, is executing a pricing, sourcing, and Quantum Leap restructuring agenda. Q2 2026 showed the results: revenue up 5.8%, adjusted EBITDA up 9%, adjusted EPS up 19%, record second-quarter cash flow of $121 million, and a 2026 guidance raise. The AMS acquisition is her defining strategic move and has drawn public opposition from Ancora Holdings, highlighting governance tension around the deal strategy.
The global adhesives and sealants market is mature and grows in the mid-single digits, driven by packaging automation, lightweighting in automotive and aerospace, construction in emerging markets, and hygiene demand. The medical adhesives segment is faster-growing at about 8% per year with regulatory barriers, which is the rationale for the AMS deal. The industry is tied to industrial production and construction cycles, and the current petrochemical supply disruption is resetting input costs.
At about 16.9x trailing earnings, 11.1x forward earnings, and 9.2x EV/EBITDA, FUL is reasonably valued on a standalone basis, with the forward multiple discounting leverage and the AMS overhang. The three-scenario range, about $51 bearish to about $100 bullish, is wide. A margin of safety would require conviction that FUL can close AMS, integrate the about $55 million of synergies, and deleverage to the 2.5x to 3x target within two years.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| FUL price | $57.01 at the August 3, 2026, 4:00 PM EDT market close, up 1.71 or 3.09% from the $55.30 July 31 close, after opening at $56.14 and trading in a session range of $56.08 to $57.31, with an after-hours quote of $55.91, down 1.10 or 1.93% | StockAnalysis.com real-time quote | August 4, 2026 |
| Market capitalization | Near $3.07 billion, reported by StockAnalysis.com at the August 3 market close and matching the $57.01 price times 53.79 million shares outstanding | StockAnalysis.com quote and statistics | August 4, 2026 |
| Enterprise value | $5.16 billion | StockAnalysis.com statistics | August 4, 2026 |
| Shares outstanding | 53.79 million shares, down about 1.46% year over year | StockAnalysis.com statistics | August 4, 2026 |
| Revenue (TTM) | $3.51 billion over the trailing twelve months ended May 30, 2026 | StockAnalysis.com financials | August 4, 2026 |
| Net income (TTM) | $185.74 million, up about 80% over the trailing year | StockAnalysis.com financials and statistics | August 4, 2026 |
| EPS (TTM) | $3.37, up about 83% over the trailing year | StockAnalysis.com financials and statistics | August 4, 2026 |
| Fiscal Q2 2026 results | Net revenue of $950.27 million, up 5.8% year over year, adjusted EBITDA of $181 million, up 9%, adjusted EBITDA margin of 19.1% up 70 basis points, adjusted gross margin of 34.2% up 200 basis points, adjusted EPS of $1.41, up 19%, and operating cash flow of $121 million, a record for a fiscal second quarter | H.B. Fuller Q2 2026 earnings release and earnings call | August 4, 2026 |
| Fiscal 2026 guidance | Adjusted EBITDA of $650 million to $675 million, adjusted EPS of $4.60 to $4.90, operating cash flow of $300 million to $325 million, net revenue up mid-single digits, organic revenue up low single digits, and foreign currency translation a positive 1% to 2% | H.B. Fuller Q2 2026 earnings call | August 4, 2026 |
| Q3 fiscal 2026 guidance | Net revenue up mid-single digits and adjusted EBITDA of $180 million to $190 million | H.B. Fuller Q2 2026 earnings call | August 4, 2026 |
| P/E ratio (TTM) | 16.91 | StockAnalysis.com statistics | August 4, 2026 |
| Forward P/E | 11.10 | StockAnalysis.com statistics | August 4, 2026 |
| P/S, P/B, P/FCF, PEG | Price to sales of 0.87, price to book of 1.47, price to free cash flow of 21.78, and PEG of 0.59 | StockAnalysis.com statistics | August 4, 2026 |
| EV/EBITDA (TTM) | 9.21 | StockAnalysis.com statistics | August 4, 2026 |
| Cash and cash equivalents | $114.10 million as of May 30, 2026, matching SEC EDGAR XBRL (114102000) from the Q2 fiscal 2026 Form 10-Q | StockAnalysis.com balance sheet and SEC EDGAR XBRL | August 4, 2026 |
| Long-term debt | $2,072.15 million as of May 30, 2026, matching SEC EDGAR XBRL (2072151000) from the Q2 fiscal 2026 Form 10-Q, with no material short-term debt | SEC EDGAR XBRL and StockAnalysis.com balance sheet | August 4, 2026 |
| Total debt | $2,072 million as of May 30, 2026 | StockAnalysis.com balance sheet | August 4, 2026 |
| Net debt | About $1,958 million, calculated as total debt of $2,072 million minus cash of $114 million | StockAnalysis.com balance sheet | August 4, 2026 |
| Shareholders equity and book value | Total shareholders equity of $2,082 million and book value per share of $37.69 as of May 30, 2026 | StockAnalysis.com balance sheet | August 4, 2026 |
| Gross, operating, and net margin (TTM) | Gross margin of about 32.0%, operating margin of about 10.8% to 12.0% depending on presentation, and net margin of about 5.3% | StockAnalysis.com financials and statistics | August 4, 2026 |
| Return on equity and ROIC | ROE of 9.39% and ROIC of 7.59% | StockAnalysis.com statistics | August 4, 2026 |
| Operating cash flow (TTM) | $322.89 million over the trailing twelve months ended May 30, 2026 | StockAnalysis.com cash flow statement | August 4, 2026 |
| Capital expenditures (TTM) | $182.12 million over the trailing twelve months ended May 30, 2026 | StockAnalysis.com cash flow statement | August 4, 2026 |
| Free cash flow (TTM) | $140.77 million over the trailing twelve months ended May 30, 2026 | StockAnalysis.com cash flow statement | August 4, 2026 |
| Dividend | Annual dividend of $0.98 per share with a 1.72% yield, quarterly payment of $0.245 declared July 16, 2026, ex-dividend date July 30, 2026, pay date August 13, 2026, payout ratio about 29%, and 57 consecutive years of dividend growth | StockAnalysis.com dividend page and Business Wire | August 4, 2026 |
| Beta (5Y) | 0.97 | StockAnalysis.com statistics | August 4, 2026 |
| 52-week range | $48.71 to $68.63, up about 2.5% over the trailing 52 weeks | StockAnalysis.com quote and statistics | August 4, 2026 |
| Short interest | 2.38 million shares short, 4.43% of shares outstanding, and about 2.33 days to cover | StockAnalysis.com statistics | August 4, 2026 |
| Moving averages and RSI | 50-day moving average of $59.42 and 200-day moving average of $60.10 on StockAnalysis.com statistics, with the 5-day near $56.11 and the 20-day near $56.19 computed from the daily price history, and 14-day RSI near 48.87 | StockAnalysis.com statistics and daily price history | August 4, 2026 |
| Analyst consensus | Strong Buy across 7 analysts with an average 12-month price target of $73.29, a low of $67, a median of $75, and a high of $80 | StockAnalysis.com forecast | August 4, 2026 |
| Recent analyst actions | Deutsche Bank Buy with target raised to $72 on June 30, Citi Buy with target raised to $75 on June 30, Seaport Global Buy with target lowered to $80 on June 26, J.P. Morgan upgraded to Buy with target raised to $67 on June 26, and UBS Hold with target raised to $71 on June 17 | StockAnalysis.com analyst ratings | August 4, 2026 |
| Fiscal 2026 and 2027 consensus | Fiscal 2026 revenue estimate of $3.64 billion with adjusted EPS of $4.87, and fiscal 2027 revenue estimate of $3.92 billion with adjusted EPS of $5.32 | StockAnalysis.com forecast | August 4, 2026 |
| AMS acquisition offer | All-cash offer for Advanced Medical Solutions at GBP 2.85 per share, enterprise value of about GBP 715 million or roughly $942 million including debt, about 12.9x pre-synergy 2026 consensus EBITDA stepping down to below 8x including the about $55 million of identified run-rate synergies, about $1 billion of committed acquisition financing, pro forma net leverage near 4x before synergies, and expected close by the end of calendar 2026 | H.B. Fuller offer announcement, Reuters, and Q2 2026 earnings call | August 4, 2026 |
This FUL AI stock analysis page is an informational research tool, not investment advice. Forecast scenarios are based on available data as of the August 4, 2026 data cutoff and may be wrong. Past performance does not guarantee future results. All investment decisions are your own responsibility. Consult a qualified financial advisor before making trading or investment decisions. Data sources include StockAnalysis.com, SEC EDGAR XBRL filings, H.B. Fuller earnings releases and the Q2 2026 earnings call, Reuters, and Business Wire. Balance sheet figures for cash and long-term debt as of May 30, 2026 cross-validated between SEC EDGAR XBRL and StockAnalysis.com. Fiscal Q2 2026 results and fiscal 2026 guidance are as disclosed by H.B. Fuller on June 25, 2026, and the AMS offer reflects terms announced June 24, 2026, which remain subject to regulatory and shareholder approval.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
